Cantor Fitzgerald Reiterates Overweight on ACADIA Pharmaceuticals, Maintains $42 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Sarah James has reiterated an Overweight rating on ACADIA Pharmaceuticals (NASDAQ:ACAD) and maintained a $42 price target.
August 22, 2023 | 1:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on ACADIA Pharmaceuticals and maintained a $42 price target.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for ACADIA Pharmaceuticals. The maintained price target of $42 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100